Inventiva Sa (IVA NASDAQ) stock market data APIs
$3.7749
0.07(1.9%)
as of June 15, 2026
Try our APIs with
free plan!
Inventiva Sa Financial Data Overview
Price chart is built with
Anychart
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Prev. Close
3.7749
Open
3.8456
High
3.8838
Low
3.7555
52 wk Range
2.8536-7.9825
Market Cap
804 M
Shares Outstanding
209 M
Revenue
6 761 K
EPS
0
Beta
0.877
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Inventiva Sa (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Inventiva Sa data using free add-ons & libraries
Get Inventiva Sa Fundamental Data
Inventiva Sa Fundamental data includes:
- Net Revenue: 6 761 K
- EBITDA: -132 497 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-25
- EPS/Forecast: -0.3436
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Inventiva Sa News
New
Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Repaid in full the existing EIB Loans1 in an amount of approximately €62 million and completed repurchase of all 2,266,023 existing EIB Tranche A Warrants and 700,000 of existing EIB Tranche B Warra...
Inventiva annonce le Remboursement des Prêts BEI, le Rachat d'une partie des BSA BEI et l'émission des deux premières tranches dans le cadre du Nouveau Financement
Remboursement intégral des Prêts BEI existants1 d'un montant d'environ 62 millions d'euros et finalisation du rachat de tous les 2,266,023 BSA Tranche A BEI existants et de 700.000 BSA Tranche B BEI...
Inventia Temporarily Halts Euronext Paris Trading Ahead Of Financing Transaction
(RTTNews) - Inventiva S.A. (Euronext Paris and Nasdaq: IVA) a clinical-stage biopharmaceutical company focused on therapies for metabolic dysfunction-associated steatohepatitis (MASH), announced that ...
Inventiva to Present Abstracts at the EASL Congress 2026
Daix (France), New York City (New York, United States), May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company f...
Get Inventiva Sa fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
